Clinical Research Directory
Browse clinical research sites, groups, and studies.
Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy
Sponsor: Peking University Cancer Hospital & Institute
Summary
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with neoadjuvant therapy
Official title: Al18F-HER2-BCH PET/CT to Predict Response in Breast Patients Treated With Neoadjuvant Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-01-01
Completion Date
2026-12-30
Last Updated
2025-04-03
Healthy Volunteers
No
Conditions
Interventions
HER2 expression of PET imaging
Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with neoadjuvant therapy
Locations (1)
Peking University Cancer Hospital & Institute
Beijing, China